Innovent Biologics Inc. has announced a new compensation plan, effective June 30, 2025, under the 2024 Share Scheme. The company granted 35,000 share options to three grantees and 497,750 restricted shares to 25 grantees. These grants are contingent upon individual annual performance targets, which are aligned with specific functional benchmarks, such as research and development, CMC, and commercialization. Additionally, a clawback mechanism has been established, allowing the company to reclaim shares or cash if certain conditions are met, such as the grantee no longer being an eligible participant. The board, led by Chairman Dr. De-Chao Michael Yu, oversees the implementation of these new compensation terms.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。